CATX · Perspective Therapeutics, Inc.

Perspective Therapeutics reported its Q1 2026 financial results, highlighting a net loss of $26.2 million compared to $18.2 million in the same period last year. The increased loss was primarily driven by a 50% rise in R&D expenses to $21.4 million, reflecting higher personnel costs, share-based compensation, and spending on clinical trials and manufacturing. G&A expenses decreased 10% to $7.0 million due to lower professional fees. The company ended the quarter with $271 million in cash and short-term investments, bolstered by a February 2026 underwritten offering that raised net proceeds of approximately $164 million. Management believes this cash runway supports planned clinical milestones into late 2027. On the clinical front, the lead program VMT-α-NET for neuroendocrine tumors is advancing toward a registration-enabling study, with Cohort 4 now open. Updated interim data were presented at AACR 2026, and the company expects meaningful regulatory engagement in 2026. The VMT01 melanoma program and PSV359 solid tumor program are also progressing, with data readouts anticipated in late 2026. Manufacturing expansion continues, with the Chicago site on track for completion this year. The company's focus on its 212Pb radiopharmaceutical platform and theranostic approach positions it for potential catalysts in the coming quarters.